Business · 04/05/1999Updated: 10/17/2026 · 1 min read
FDA Announces Public Meeting to Discuss Approach to Assessing Preclinical Reproductive Toxicity Data
Summary
The FDA is hosting a public meeting to discuss its approach to evaluating preclinical data on reproductive toxicity in pharmaceuticals, with the goal of informing guidance on pharmaceutical reproductive risk.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →